Clinical efficacy of Valsartan sodium administrated in patients with heart failure
Yan Xianliang
Gao Yulong
Tao Ying
Lin Yun
Zhang Jingmei
Li Zhizhong
Abstract：study the clinical efficacy of Nuoxintuo (sacubitril/valsartan) in administrated patients with heart failure (HF). Methods The patients with heart failure with reduced ejection fraction (HFrEF, n=43) were chosen continuously from Beijing Anzhen Hospital of Capital University of Medical Sciences for Oct. 2017 to Apr. 2018. The patients were randomly divided into Nuoxintuo group (n=17) and enalapril group (n=26). The observation indexes were major adverse cardiovascular events (MACE) including cardiac death and rehospitalization due to HF recurrence, indexes of echocardiogram including left ventricular end-diastolic inner diameter (LVEDd), increased value of LVEDd (△-LVEDd), left ventricular ejection fraction (LVEF) and increased value of LVEF (△-LVEF), and level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and increased value of NT-proBNP (△-NT proBNP). Results The rate of cardiac death was 5.9% in Nuoxintuo group and 7.7% in enalapril group without statistical difference. The rate of rehospitalization due to HF recurrence was 11.7% in Nuoxintuo group and 23.1% in enalapril group and the difference had statistical significance. The levels of LVEDd (a) and NT-proBNP (a) were lower in Nuoxintuo group than those in enalapril group and the difference had statistical significance. The levels of LVEF (a), △-LVEDd, △-LVEF and △-NT-proBNP were higher in Nuoxintuo group than those in enalapril group and the difference had statistical significance. Conclusion Nuoxintuo can be administrated safely and effectively in patients with HFrEF.
Keywords：Valsartan sodium (sacubitril/valsartan)EnalaprilHeart failure with reduced ejection fraction
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1248-1250,1254 )